{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:27:55Z","timestamp":1765700875896,"version":"3.38.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T00:00:00Z","timestamp":1291334400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10637-010-9590-4","type":"journal-article","created":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T04:16:43Z","timestamp":1291263403000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Deactylase inhibition in myeloproliferative neoplasms"],"prefix":"10.1007","volume":"28","author":[{"given":"Sridurga","family":"Mithraprabhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Khong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,3]]},"reference":[{"key":"9590_CR1","volume-title":"World health organisation classification of tumours of haemopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) World health organisation classification of tumours of haemopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC) Press, Lyon"},{"key":"9590_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer Statistics, 2007. CA Cancer J Clin 57:43\u201366","journal-title":"CA Cancer J Clin"},{"key":"9590_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02137.x","volume":"110","author":"CG Geary","year":"2000","unstructured":"Geary CG (2000) The story of chronic myeloid leukaemia. Br J Haematol 110:2\u201311","journal-title":"Br J Haematol"},{"key":"9590_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2003.50004","volume":"40","author":"M Baccarini","year":"2003","unstructured":"Baccarini M, Russo D, Rosti G, Martinelli G (2003) Interferon-alfa for chronic myeloid leukemia. Semin Hematol 40:22\u201333","journal-title":"Semin Hematol"},{"key":"9590_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarini","year":"2006","unstructured":"Baccarini M, Saglio G, Goldman L et al (2006) Evolving concepts in the management of chronc myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"9590_CR6","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513\u2013521","journal-title":"Haematologica"},{"key":"9590_CR7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"9590_CR8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O\u2019Brien S, Cortes J (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern 145:913\u2013923","journal-title":"Ann Intern"},{"key":"9590_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345\u2013256","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"9590_CR10","doi-asserted-by":"publisher","first-page":"34227","DOI":"10.1074\/jbc.M402290200","volume":"279","author":"Y Dai","year":"2004","unstructured":"Dai Y et al (2004) A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279(33):34227\u201334239","journal-title":"J Biol Chem"},{"issue":"2","key":"9590_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","volume":"64","author":"NJ Donato","year":"2004","unstructured":"Donato NJ et al (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64(2):672\u2013677","journal-title":"Cancer Res"},{"issue":"3","key":"9590_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1124\/jpet.107.124461","volume":"322","author":"SM Lee","year":"2007","unstructured":"Lee SM et al (2007) Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 322(3):1084\u20131092","journal-title":"J Pharmacol Exp Ther"},{"key":"9590_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/j.1582-4934.2009.00827.x","volume":"13","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T (2009) Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med 13:1437\u20131450","journal-title":"J Cell Mol Med"},{"key":"9590_CR14","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","volume":"107","author":"AV Jones","year":"2006","unstructured":"Jones AV, Silver RT, Waghorn et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339\u20133341","journal-title":"Blood"},{"key":"9590_CR15","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"122","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 122:1990\u20131998","journal-title":"Leukemia"},{"key":"9590_CR16","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S et al (2008) Pegylated Interferon-alfa-2a induces complete haematological and molecular responses with low toxicity in polycythemia vera. Blood 112:3065\u20133072","journal-title":"Blood"},{"key":"9590_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/leu.2008.136","volume":"23","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Verstovek S, Rivera C et al (2009) 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 23:180\u2013182","journal-title":"Leukemia"},{"key":"9590_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/PPO.0b013e31815a7c0a","volume":"13","author":"F Cervantes","year":"2007","unstructured":"Cervantes F, Mesa R, Barosi G (2007) New and old treatment modalities in primary myelofibrosis. Cancer J 13:377\u2013383","journal-title":"Cancer J"},{"key":"9590_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/sj.leu.2404816","volume":"21","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Camoriano JK, Geyer SM et al (2007) A phase II trial of tifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 21:1964\u20131970","journal-title":"Leukemia"},{"key":"9590_CR20","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/leu.2008.32","volume":"22","author":"RA Mesa","year":"2008","unstructured":"Mesa RA, Verstovsek S, Rivera C et al (2008) Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 22:1636\u20131638","journal-title":"Leukemia"},{"key":"9590_CR21","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Lasho TL, Mesa RA et al (2007) Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 21:1827\u20131828","journal-title":"Leukemia"},{"key":"9590_CR22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109\u20133117","journal-title":"Blood"},{"issue":"Spec No 1","key":"9590_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/hmg\/ddm018","volume":"16","author":"M Esteller","year":"2007","unstructured":"Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16(Spec No 1):50\u201359","journal-title":"Hum Mol Genet"},{"issue":"4","key":"9590_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"MF Fraga","year":"2005","unstructured":"Fraga MF et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4):391\u2013400","journal-title":"Nat Genet"},{"issue":"1","key":"9590_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O et al (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277(1):8\u201321","journal-title":"Cancer Lett"},{"issue":"5\u20136","key":"9590_CR26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/PL00000896","volume":"58","author":"S Timmermann","year":"2001","unstructured":"Timmermann S et al (2001) Histone acetylation and disease. Cell Mol Life Sci 58(5\u20136):728\u2013736","journal-title":"Cell Mol Life Sci"},{"key":"9590_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/ng1860","volume":"38","author":"S Shi","year":"2006","unstructured":"Shi S, Calhoun HC, Xia F et al (2006) JAK signalling globally counteracts heterochromatic gene silencing. Nat Genet 38:1071\u20131076","journal-title":"Nat Genet"},{"key":"9590_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1182\/blood-2005-08-007377","volume":"108","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Wang HY, Woetmannn A et al (2006) STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T cells. Blood 108:1058\u20131064","journal-title":"Blood"},{"key":"9590_CR29","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1080\/10428190802578866","volume":"49","author":"A Tefferi","year":"2008","unstructured":"Tefferi A (2008) Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leuk Lymphoma 49:2231\u20132232","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"9590_CR30","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1080\/10428190802527699","volume":"49","author":"JC Wang","year":"2008","unstructured":"Wang JC et al (2008) Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 49(12):2321\u20132327","journal-title":"Leuk Lymphoma"},{"key":"9590_CR31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3324\/haematol.13043","volume":"93","author":"N Fourcouclas","year":"2008","unstructured":"Fourcouclas N, Li J, Gilby DC et al (2008) Methylation of the suppressor of cytokine signalling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93:1635\u20131644","journal-title":"Haematologica"},{"key":"9590_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1365-2141.2008.07072.x","volume":"141","author":"D Capello","year":"2008","unstructured":"Capello D, Deambrogi C, Rossi D et al (2008) Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 141:504\u2013511","journal-title":"Br J Haematol"},{"key":"9590_CR33","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.leukres.2008.03.014","volume":"32","author":"M Fernandez-Mercado","year":"2008","unstructured":"Fernandez-Mercado M, Cebrian V, Euba B et al (2008) Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res 32:1638\u20131640","journal-title":"Leuk Res"},{"key":"9590_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.leu.2404513","volume":"21","author":"E Jost","year":"2007","unstructured":"Jost E, do ON, Dahl E (2007) Epigenetic alterations complement mutations of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders. Leukemia 21:505\u2013510","journal-title":"Leukemia"},{"key":"9590_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","volume":"25","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Zini R, Bogani C et al (2007) Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1). Stem Cells 25:165\u2013173","journal-title":"Stem Cells"},{"key":"9590_CR36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bcmd.2007.01.003","volume":"38","author":"V Rosti","year":"2007","unstructured":"Rosti V, Massa M, Vannucchi AM et al (2007) The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 38:280\u2013286","journal-title":"Blood Cells Mol Dis"},{"key":"9590_CR37","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","volume":"26","author":"C Bogani","year":"2008","unstructured":"Bogani C, Ponziani V, Gugliemelli P et al (2008) Hypermethylation of CXCR4 promoter in the CD34+ cells from patients with primary myelofibrosis. Stem Cells 26:1920\u20131930","journal-title":"Stem Cells"},{"key":"9590_CR38","doi-asserted-by":"crossref","first-page":"101A","DOI":"10.1182\/blood.V112.11.101.101","volume":"112","author":"X Wang","year":"2008","unstructured":"Wang X, Zhang W, Ishii T et al (2008) Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin modifying agents. Blood 112:101A","journal-title":"Blood"},{"key":"9590_CR39","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440","journal-title":"J Clin Oncol"},{"key":"9590_CR40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V110.11.817.817","volume":"110","author":"P Fenaux","year":"2007","unstructured":"Fenaux P, Mufti GJ, Santini V et al (2007) Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR). Blood 110:817","journal-title":"Blood"},{"key":"9590_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/leu.2008.91","volume":"22","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Tong W, Kantarjian H et al (2008) A phase II study of 5-Azacitidine for patients with primary and post essential thrombocythemia\/polycythemia vera myelofibrosis. Leukemia 22:965\u2013970","journal-title":"Leukemia"},{"issue":"1","key":"9590_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M et al (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10(1):32\u201342","journal-title":"Nat Rev Genet"},{"issue":"19","key":"9590_CR43","doi-asserted-by":"publisher","first-page":"7751","DOI":"10.1073\/pnas.0903139106","volume":"106","author":"M Haberland","year":"2009","unstructured":"Haberland M et al (2009) Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 106(19):7751\u20137755","journal-title":"Proc Natl Acad Sci USA"},{"key":"9590_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","volume":"86","author":"H Lehrmann","year":"2002","unstructured":"Lehrmann H et al (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41\u201365","journal-title":"Adv Cancer Res"},{"issue":"3","key":"9590_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/med.20024","volume":"25","author":"A Mai","year":"2005","unstructured":"Mai A et al (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25(3):261\u2013309","journal-title":"Med Res Rev"},{"issue":"1","key":"9590_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","volume":"41","author":"S Spange","year":"2009","unstructured":"Spange S et al (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41(1):185\u2013198","journal-title":"Int J Biochem Cell Biol"},{"key":"9590_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"MA Glozak","year":"2005","unstructured":"Glozak MA et al (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15\u201323","journal-title":"Gene"},{"issue":"37","key":"9590_CR48","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA et al (2007) Histone deacetylases and cancer. Oncogene 26(37):5420\u20135432","journal-title":"Oncogene"},{"issue":"24","key":"9590_CR49","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/jm0303094","volume":"46","author":"TA Miller","year":"2003","unstructured":"Miller TA et al (2003) Histone deacetylase inhibitors. J Med Chem 46(24):5097\u20135116","journal-title":"J Med Chem"},{"issue":"9","key":"9590_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE et al (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769\u2013784","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"9590_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S et al (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38\u201351","journal-title":"Nat Rev Cancer"},{"issue":"37","key":"9590_CR52","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS et al (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37):5541\u20135552","journal-title":"Oncogene"},{"issue":"25","key":"9590_CR53","doi-asserted-by":"publisher","first-page":"22491","DOI":"10.1074\/jbc.M100206200","volume":"276","author":"H Brinkmann","year":"2001","unstructured":"Brinkmann H et al (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 276(25):22491\u201322499","journal-title":"J Biol Chem"},{"issue":"40","key":"9590_CR54","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","volume":"23","author":"A Burgess","year":"2004","unstructured":"Burgess A et al (2004) Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23(40):6693\u20136701","journal-title":"Oncogene"},{"issue":"4","key":"9590_CR55","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0026-895X(24)12311-5","volume":"60","author":"AJ Burgess","year":"2001","unstructured":"Burgess AJ et al (2001) Up-regulation of p21(WAF1\/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60(4):828\u2013837","journal-title":"Mol Pharmacol"},{"issue":"6","key":"9590_CR56","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","volume":"11","author":"L Qiu","year":"2000","unstructured":"Qiu L et al (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11(6):2069\u20132083","journal-title":"Mol Biol Cell"},{"issue":"6","key":"9590_CR57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4161\/cc.4.6.1717","volume":"4","author":"A Insinga","year":"2005","unstructured":"Insinga A et al (2005) Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 4(6):741\u2013743","journal-title":"Cell Cycle"},{"issue":"7","key":"9590_CR58","first-page":"2049","volume":"60","author":"MW Deininger","year":"2000","unstructured":"Deininger MW et al (2000) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60(7):2049\u20132055","journal-title":"Cancer Res"},{"issue":"9","key":"9590_CR59","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG et al (2002) Imatinib mesylate\u2013a new oral targeted therapy. N Engl J Med 346(9):683\u2013693","journal-title":"N Engl J Med"},{"issue":"5531","key":"9590_CR60","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876\u2013880","journal-title":"Science"},{"issue":"2","key":"9590_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117\u2013125","journal-title":"Cancer Cell"},{"issue":"2","key":"9590_CR62","first-page":"281","volume":"5","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG et al (2009) Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 5(2):281\u2013289","journal-title":"Ther Clin Risk Manag"},{"key":"9590_CR63","first-page":"89","volume":"3","author":"R Swords","year":"2009","unstructured":"Swords R et al (2009) Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3:89\u2013101","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"9590_CR64","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","volume":"108","author":"W Fiskus","year":"2006","unstructured":"Fiskus W et al (2006) Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108(2):645\u2013652","journal-title":"Blood"},{"issue":"4","key":"9590_CR65","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George P et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105(4):1768\u20131776","journal-title":"Blood"},{"issue":"5","key":"9590_CR66","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cncr.21725","volume":"106","author":"A Morotti","year":"2006","unstructured":"Morotti A et al (2006) Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 106(5):1188\u20131196","journal-title":"Cancer"},{"issue":"16","key":"9590_CR67","first-page":"5126","volume":"63","author":"R Nimmanapalli","year":"2003","unstructured":"Nimmanapalli R et al (2003) Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63(16):5126\u20135135","journal-title":"Cancer Res"},{"issue":"8","key":"9590_CR68","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","volume":"101","author":"R Nimmanapalli","year":"2003","unstructured":"Nimmanapalli R et al (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101(8):3236\u20133239","journal-title":"Blood"},{"issue":"1","key":"9590_CR69","first-page":"169","volume":"15","author":"Y Xu","year":"2005","unstructured":"Xu Y et al (2005) The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 15(1):169\u2013172","journal-title":"Int J Mol Med"},{"issue":"3","key":"9590_CR70","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2007-10-116376","volume":"112","author":"Y Dai","year":"2008","unstructured":"Dai Y et al (2008) Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 112(3):793\u2013804","journal-title":"Blood"},{"issue":"1","key":"9590_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood-2006-10-050260","volume":"110","author":"JS Carew","year":"2007","unstructured":"Carew JS et al (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110(1):313\u2013322","journal-title":"Blood"},{"issue":"19","key":"9590_CR72","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","volume":"12","author":"W Fiskus","year":"2006","unstructured":"Fiskus W et al (2006) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12(19):5869\u20135878","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9590_CR73","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.leu.2403868","volume":"19","author":"C Yu","year":"2005","unstructured":"Yu C et al (2005) Synergistic interactions between MEK1\/2 and histone deacetylase inhibitors in BCR\/ABL+ human leukemia cells. Leukemia 19(9):1579\u20131589","journal-title":"Leukemia"},{"key":"9590_CR74","doi-asserted-by":"crossref","unstructured":"Kalle AM et al (2010) Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res","DOI":"10.1016\/j.leukres.2010.01.030"},{"issue":"5","key":"9590_CR75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1517\/13543784.16.5.659","volume":"16","author":"WK Rasheed","year":"2007","unstructured":"Rasheed WK et al (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16(5):659\u2013678","journal-title":"Expert Opin Investig Drugs"},{"issue":"19","key":"9590_CR76","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","volume":"14","author":"W Fiskus","year":"2008","unstructured":"Fiskus W et al (2008) Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14(19):6106\u20136115","journal-title":"Clin Cancer Res"},{"issue":"14","key":"9590_CR77","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-07-0835","volume":"13","author":"G Dasmahapatra","year":"2007","unstructured":"Dasmahapatra G et al (2007) Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 13(14):4280\u20134290","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9590_CR78","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","volume":"102","author":"C Yu","year":"2003","unstructured":"Yu C et al (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571. Blood 102(10):3765\u20133774","journal-title":"Blood"},{"issue":"11","key":"9590_CR79","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.yexcr.2009.02.024","volume":"315","author":"SJ Park","year":"2009","unstructured":"Park SJ et al (2009) Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp Cell Res 315(11):1809\u20131818","journal-title":"Exp Cell Res"},{"issue":"5A","key":"9590_CR80","first-page":"2705","volume":"24","author":"T Kawano","year":"2004","unstructured":"Kawano T et al (2004) Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res 24(5A):2705\u20132712","journal-title":"Anticancer Res"},{"issue":"3","key":"9590_CR81","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/scd.2007.9994","volume":"16","author":"S Okabe","year":"2007","unstructured":"Okabe S et al (2007) Depsipeptide (FK228) preferentially induces apoptosis in BCR\/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 16(3):503\u2013514","journal-title":"Stem Cells Dev"},{"issue":"1","key":"9590_CR82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-0609.2009.01242.x","volume":"83","author":"B Kircher","year":"2009","unstructured":"Kircher B et al (2009) Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ALL and CML cells in vitro. Eur J Haematol 83(1):48\u201356","journal-title":"Eur J Haematol"},{"issue":"3","key":"9590_CR83","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bcmd.2006.08.001","volume":"37","author":"D Grebenova","year":"2006","unstructured":"Grebenova D et al (2006) The proteomic study of sodium butyrate antiproliferative\/cytodifferentiation effects on K562 cells. Blood Cells Mol Dis 37(3):210\u2013217","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"9590_CR84","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.leukres.2006.12.015","volume":"31","author":"E Rabizadeh","year":"2007","unstructured":"Rabizadeh E et al (2007) Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk Res 31(8):1115\u20131123","journal-title":"Leuk Res"},{"issue":"5","key":"9590_CR85","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang B et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17(5):427\u2013442","journal-title":"Cancer Cell"},{"issue":"26","key":"9590_CR86","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/sj.onc.1201899","volume":"16","author":"N Bissonnette","year":"1998","unstructured":"Bissonnette N et al (1998) p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16(26):3461\u20133469","journal-title":"Oncogene"},{"issue":"5","key":"9590_CR87","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.onc.1202409","volume":"18","author":"A Suzuki","year":"1999","unstructured":"Suzuki A et al (1999) Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18(5):1239\u20131244","journal-title":"Oncogene"},{"issue":"50","key":"9590_CR88","doi-asserted-by":"publisher","first-page":"39223","DOI":"10.1074\/jbc.M007291200","volume":"275","author":"F Gesbert","year":"2000","unstructured":"Gesbert F et al (2000) BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway. J Biol Chem 275(50):39223\u201339230","journal-title":"J Biol Chem"},{"issue":"29","key":"9590_CR89","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"Bali P et al (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280(29):26729\u201326734","journal-title":"J Biol Chem"},{"issue":"5","key":"9590_CR90","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","volume":"112","author":"R Rao","year":"2008","unstructured":"Rao R et al (2008) HDAC6 inhibition enhances 17-AAG\u2013mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112(5):1886\u20131893","journal-title":"Blood"},{"issue":"5","key":"9590_CR91","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1097-2765(04)00094-2","volume":"13","author":"HY Cohen","year":"2004","unstructured":"Cohen HY et al (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13(5):627\u2013638","journal-title":"Mol Cell"},{"issue":"27","key":"9590_CR92","doi-asserted-by":"publisher","first-page":"20436","DOI":"10.1074\/jbc.M000202200","volume":"275","author":"LJ Juan","year":"2000","unstructured":"Juan LJ et al (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275(27):20436\u201320443","journal-title":"J Biol Chem"},{"issue":"12","key":"9590_CR93","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.freeradbiomed.2006.02.014","volume":"40","author":"S Kume","year":"2006","unstructured":"Kume S et al (2006) Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 40(12):2175\u20132182","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"9590_CR94","first-page":"375","volume":"33","author":"LG Wang","year":"2008","unstructured":"Wang LG et al (2008) De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33(2):375\u2013380","journal-title":"Int J Oncol"},{"issue":"4","key":"9590_CR95","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2008","unstructured":"Guerini V et al (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22(4):740\u2013747","journal-title":"Leukemia"},{"issue":"13","key":"9590_CR96","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","volume":"67","author":"J Shi","year":"2007","unstructured":"Shi J et al (2007) Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 67(13):6417\u20136424","journal-title":"Cancer Res"},{"key":"9590_CR97","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Dellacasa CM, Salmoiraghi S et al (2008) A phase 2A study of the histone-deacetlase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. 112:110A","DOI":"10.1182\/blood.V112.11.100.100"},{"issue":"24","key":"9590_CR98","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","volume":"114","author":"Y Wang","year":"2009","unstructured":"Wang Y et al (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114(24):5024\u20135033","journal-title":"Blood"},{"key":"9590_CR99","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood.V114.22.2898.2898","volume":"114","author":"DJ DeAngelo","year":"2009","unstructured":"DeAngelo DJ, Spencer A, Fischer T et al (2009) Activity of oral panobinostat (LBH589) in patients with myelofibrosis. Blood 114:2898","journal-title":"Blood"},{"key":"9590_CR100","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2009-06-230037","volume":"114","author":"J Mascareenhas","year":"2009","unstructured":"Mascareenhas J, Wang X, Rodriguez A (2009) A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (Post-PV\/ET MF). Blood 114:308","journal-title":"Blood"},{"issue":"7","key":"9590_CR101","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00277-008-0640-3","volume":"88","author":"J Lee","year":"2009","unstructured":"Lee J (2009) Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol 88(7):699\u2013700","journal-title":"Ann Hematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10637-010-9590-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:55:18Z","timestamp":1740740118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":101,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9590"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9590-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"27 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}